Cingulate (CINGW) Research & Development (2021 - 2026)
Cingulate's (CINGW) quarterly Research & Development came in at $1.5 million in Q2 2026, down 44.95% on a YoY basis from $2.7 million in Q2 2025, and down 25.73% quarter-over-quarter from $2.0 million in Q4 2025.
Analysis
Cingulate (CINGW) Research & Development (2021 - 2026) Analysis & Trends
Cingulate (CINGW) has reported Research & Development for 6 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Research & Development fell 44.95% year-over-year to $1.5 million; the trailing twelve-month figure through Jun 2026 stood at $9.0 million (down 15.38% YoY), and the FY2025 full-year result was $9.8 million, up 3.48% from the prior year.
- Research & Development eased to $1.5 million in Q2 2026 per CINGW's latest filing, from $2.0 million in the prior quarter.
- Across five years, Research & Development topped out at $5.0 million in Q4 2023 and bottomed at $1.4 million in Q3 2024.
- Historically, Research & Development has averaged $2.7 million across 5 years, with a median of $2.2 million in 2022.
- The sharpest annual moves came in 2022 and 2024: Research & Development surged 391.06% in 2022, then sank 63.59% in 2024.
- Over 5 years, Research & Development stood at $1.9 million in 2022, then jumped by 158.06% to $5.0 million in 2023, then retreated by 13.16% to $4.3 million in 2024, then sank by 53.75% to $2.0 million in 2025, then decreased by 25.73% to $1.5 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $1.5 million, $2.0 million, and $2.8 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.70 Bn | 623.94 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 441.16 Bn | 434.59 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 364.92 Bn | 357.78 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 266.48 Bn | 258.79 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn | 2.81 Bn |
| 6 | Sanofi | 52.53 Bn | 45.15 Bn | 10.79 Bn | -2.60 Bn |
| 7 | Revolution Medicines | 44.20 Bn | 44.20 Bn | - | 394.92 Mn |
| 8 | Incyte | 25.27 Bn | 20.74 Bn | 1.57 Bn | 516.95 Mn |
| 9 | United Therapeutics | 21.44 Bn | 18.78 Bn | 683.80 Mn | 146.30 Mn |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - | 1.49 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.49 Mn |
| Dec 31, 2025 | 2.00 Mn |
| Sep 30, 2025 | 2.85 Mn |
| Jun 30, 2025 | 2.70 Mn |
| Mar 31, 2025 | 2.22 Mn |
| Dec 31, 2024 | 4.33 Mn |
| Sep 30, 2024 | 1.43 Mn |
| Jun 30, 2024 | 1.88 Mn |
| Mar 31, 2024 | 1.81 Mn |
| Dec 31, 2023 | 4.98 Mn |
| Sep 30, 2023 | 3.92 Mn |
| Jun 30, 2023 | 4.46 Mn |
| Mar 31, 2023 | 2.13 Mn |
| Dec 31, 2022 | 1.93 Mn |
| Sep 30, 2022 | 2.12 Mn |
| Jun 30, 2022 | 2.18 Mn |
| Mar 31, 2022 | 2.76 Mn |
| Dec 31, 2021 | 1.26 Mn |
| Sep 30, 2021 | 5.79 Mn |
| Jun 30, 2021 | 793,587.00 |